Case Report of COVID-19 Infection After Kidney Transplant Treated With Casirivimab-Imdevimab and Mycophenolate Mofetil Changed to Everolimus

BACKGROUND: Casirivimab-imdevimab is a cocktail of 2 monoclonal antibodies designed to prevent infection by SARS-CoV-2, the virus that causes COVID-19. Casirivimab-imdevimab has been approved in Japan for treating mild to moderate COVID-19; however, to our knowledge, there are no reports of its use...

Descripción completa

Detalles Bibliográficos
Autores principales: Kijima, Yu, Shimizu, Tomokazu, Kato, Shinya, Kano, Kana, Horiuchi, Toshihide, Nozaki, Taiji, Omoto, Kazuya, Inui, Masashi, Toma, Hiroshi, Iida, Shoichi, Takagi, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718884/
https://www.ncbi.nlm.nih.gov/pubmed/35065832
http://dx.doi.org/10.1016/j.transproceed.2021.12.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718884/
https://www.ncbi.nlm.nih.gov/pubmed/35065832
http://dx.doi.org/10.1016/j.transproceed.2021.12.018

Ejemplares similares